治疗高血压的损伤:选择和转诊患者的关键因素
Michael A Weber1, Eric A Secemsky2, Anna Krawisz2
1Division of Cardiovascular Medicine, SUNY Downstate Medical Center, Brooklyn, NY, United States of America.
概括
脏缩 (RDN) 为无法控制的高血压提供了一种新的治疗方法. 本文概述了将RDN转诊途径整合到医疗保健系统中的模型,以改善患者的访问和结果.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 耐性高血压影响许多患者,尽管改变生活方式和药物治疗.
- 脏缩 (RDN) 是一种经批准的治疗方法,用于难以控制的高血压.
- 有效的患者转介途径对于RDN可访问性至关重要.
研究的目的:
- 探索将RDN整合到临床实践中的程序模型.
- 讨论创建RDN可访问的患者转诊途径的策略.
- 优化 RDN 的应用,以改善高血压管理.
主要方法:
- 审查当前医疗保健系统结构的高血压管理.
- 对分散式和集中式 RDN 程序模型的分析.
- 考虑患者选择标准和基于团队的护理方法.
主要成果:
- 检查清单可以促进社区实践中的患者选择.
- 集中式和分散式的模型提供了不同的整合方法.
- 多学科团队是成功选择患者和RDN计划管理的关键.
结论:
- 实施结构化的RDN转介途径可以增强患者获得这种治疗的机会.
- 专家团队仔细选择患者对于RDN的有效性至关重要.
- 优化 RDN 集成可以改善高血压控制和降低心血管风险.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
513
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
513
Antihypertensive Drugs: Direct Renin Inhibitors
833
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
833
Antihypertensive Drugs: Action of Diuretics
877
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
877
Antihypertensive Drugs: Vasodilators
646
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
646
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
892
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
892
Antihypertensive Drugs: Action of β1 Blockers
614
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
614


